Methods

The study was a single-center (Canada), single-arm, open-label, single-dose drug-drug interaction study in healthy volunteers (Study 1604; EudraCT Number: 2016-002804-14; conducted by Syneos Health™; Zogenix, Inc., Emeryville, CA, USA).

The study was a Phase 1, single-center (Canada), 1-sequence, single-dose drug-drug interaction study in healthy volunteers.

The purpose of the study was to assess the tolerability and PK profiles of FFA and its major metabolite, norfenfluramine (norFFA), following a single dose of FFA oral solution (0.35 mg/kg), with and without steady-state coadministration of CBD in healthy volunteers.

FFA has also demonstrated efficacy and durability of seizure reduction in patients with LGS and Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) and is under evaluation in Phase 3 studies for LGS.

The study was a Phase 1, single-center (Canada), 1-sequence, single-dose drug-drug interaction study in healthy volunteers.

The study was a Phase 1, single-center (Canada), 1-sequence, single-dose drug-drug interaction study in healthy volunteers. The study was a Phase 1, single-center (Canada), 1-sequence, single-dose drug-drug interaction study in healthy volunteers.

The study was a Phase 1, single-center (Canada), 1-sequence, single-dose drug-drug interaction study in healthy volunteers. The study was a Phase 1, single-center (Canada), 1-sequence, single-dose drug-drug interaction study in healthy volunteers. The study was a Phase 1, single-center (Canada), 1-sequence, single-dose drug-drug interaction study in healthy volunteers. The study was a Phase 1, single-center (Canada), 1-sequence, single-dose drug-drug interaction study in healthy volunteers.

The study was a Phase 1, single-center (Canada), 1-sequence, single-dose drug-drug interaction study in healthy volunteers. The study was a Phase 1, single-center (Canada), 1-sequence, single-dose drug-drug interaction study in healthy volunteers. The study was a Phase 1, single-center (Canada), 1-sequence, single-dose drug-drug interaction study in healthy volunteers.

The study was a Phase 1, single-center (Canada), 1-sequence, single-dose drug-drug interaction study in healthy volunteers.